|
US2021102209A1
|
|
Compositions and Methods for Treating, Ameliorating, and/or Preventing Viral Infections
|
|
US2021123064A1
|
|
Engineering organisms resistant to viruses and horizontally transferred genetic elements
|
|
WO2021077070A1
|
|
Compositions and methods for inhibition of cell-penetrating antibodies
|
|
US2021109045A1
|
|
Continuous scanning for localization microscopy
|
|
WO2021072269A1
|
|
Targeted bifunctional degraders
|
|
WO2021072246A1
|
|
Engineered antibodies as molecular degraders through cellular receptors
|
|
WO2021072276A1
|
|
Compositions and methods for upregulating isoforms of dystrophin as therapy for duchenne muscular dystrophy (dmd)
|
|
WO2021072079A1
|
|
A gene associated with human reading performance
|
|
WO2021067752A1
|
|
Targeting cap-dependent translation to reduce seizures in mtor disorders
|
|
US2021102950A1
|
|
Compositions and methods for enrichment and detection of ubiquitin and ubiquitin conjugates
|
|
US2021093441A1
|
|
Transcatheter device, system and method for treating type a aortic dissection
|
|
US2021095331A1
|
|
Deterministic barcoding for spatial omics sequencing
|
|
WO2021062128A1
|
|
Methods and compositions for treating a disease or disorder
|
|
WO2021055564A1
|
|
Methods of treating phosphate concentration disorders with l-baiba
|
|
WO2021050743A1
|
|
Compositions and methods for treating slow-flow vascular malformations
|
|
WO2021050568A1
|
|
Nanoparticles for selective tissue or cellular uptake
|
|
WO2021042060A1
|
|
Compositions and methods for delivery of nucleic acids to cells
|
|
WO2021041298A1
|
|
Portable and compact system for delivery of humidified high flow nasal cannula (hhfnc) therapy in neonates and infants
|
|
WO2021030427A2
|
|
Intragel well sample loading system
|
|
WO2021022161A1
|
|
Compositions and methods for treating sickle cell disease
|
